Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Parish

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
JAMA|April 28, 2005
Obesity and the risk of new-onset atrial fibrillationDaniel Parish
Current Opinion in Investigational Drugs (London, England : 2000)|February 5, 2008
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infectionDaniel Parish, Noah Scheinfeld
Drugs of Today (Barcelona, Spain : 1998)|February 28, 2008
Desonide foam: a reviewDaniel Parish, Noah Scheinfeld
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasisNoah Scheinfeld, Daniel Parish
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
JAMA|April 28, 2005
Obesity and the risk of new-onset atrial fibrillationDaniel Parish
Current Opinion in Investigational Drugs (London, England : 2000)|February 5, 2008
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infectionDaniel Parish, Noah Scheinfeld
Drugs of Today (Barcelona, Spain : 1998)|February 28, 2008
Desonide foam: a reviewDaniel Parish, Noah Scheinfeld
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasisNoah Scheinfeld, Daniel Parish
Pageof 1